The global chemotherapy-induced nausea and vomiting (CINV) market is expected to reach USD 1.7 billion by 2015, due to prevalent cancer related conditions and subsequent increase in the CINV pool. The global CINV patient pool is estimated to reach 4.6 million by 2015. The Asian region is expected to witness the largest patient share for CINV contributing majorly to the total CINV patient pool thereby presenting a huge potential for the Netupitant - Palonosetron market. This report initially starts with the thorough analysis of the CINV market, its potential, the target patient pool, with forecast period covering 2009-2015. This report also covers the basic knowledge of the Netupitant - Palonosetron FDC and its mode of action, along with an estimation of their sales projection, current scenario, SWOT analysis, clinical trials and opportunities. It also covers the factors driving this market and the regional analysis including United States, Europe, Australia and UK among others. The present market condition and performance has been mentioned in detail along with the CINV patient pool. Moreover, the report provides in-depth analysis of Netupitant - Palonosetron FDC market with their estimated and forecast market size till 2018.
This in-depth analysis of Netupitant-Palonosetron FDC market helps provide an understanding of the various driving factors for the growth of the market. The market overview section of this report analyzes the market dynamics and trends with the help of SWOT analysis, which influence the current nature and future status of this market. SWOT analysis includes strength, weakness opportunities and threats for the Netupitant-Palonosetron FDC manufacturer. Global CINV market qualitative study is also been presented in this report, this covers the impact of CINV in for Netupitant - Palonosetron FDC market. Impact factors such as market attractiveness analysis, that includes the study of target patient pool, and sales projection analysis with forecast of the sales in terms of USD for the decade 2000-2010, these sections have also been quantitatively explained in the market overview section of the report in order to deliver a thorough analysis of the overall competitive scenario of the global Netupitant - Palonosetron FDC market.
The report further discusses the Netupitant - Palonosetron FDC market on the basis of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). The clinical trial details are segregated into part 1 and 2, each with their own section of guidelines, detailed information and outcome. We have also mapped the trend for preference of the pharmaceutical players for overall license agreement of the Netupitant - Palonosetron FDC market globally as per regions.
The Netupitant - Palonosetron FDC market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2012 to 2018 have been provided for each of the segments, in term of USD million, considering 2011 as the base year for calculations and 2010 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations.
The report exclusively studies the Overall License Agreement for Netupitant - Palonosetron FDC with respect to geography. Under geographic section we have covered four continents that specifically include a few developed countries in focus namely: United States, Europe, Australia, UK, Ireland, and South Korea.
The report concludes with the competitive landscape and company profiles of Helsinn Group on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments.
Table of Content
1.1. Report Description
1.2. Research Methodology
1.1.1. Therapeutic Classes
1.1.2. Order of Entry into the Market
1.1.4. Dosage & Formulation Type
1.1.1. Company Overview
1.1.2. Business Strategy
1.1.3. Financial Overview
1.1.4. Products and Services
1.1.5. Recent Developments
2. Executive Summary and Market Overview
3. Market Analysis
3.1. Introduction: Chemotherapy Induced Nausea and Vomiting (CINV)
3.1.2. Aetiology/Causes for CINV
3.1.3. Current Drug Treatment Available
3.2. CINV Market Size & Opportunity Scenario (1/2)
3.2.1. Global CINV Market (USD Million), 2009 - 2015
3.2.2. CINV Market (USD Million), by Geography, 2009 – 2015
3.2.3. Global CINV Patient Pool (Million), 2009 – 2015
3.2.4. CINV Target Patient Pool, by Geography, 2009 - 2015
3.3. Description of Netupitant - Palonosetron FDC
3.4. Mechanism of Action of Netupitant - Palonosetron FDC
3.5. Clinical Trials Detail
3.5.1. Clinical Trial Detail – 1
126.96.36.199. Trials Id - NCT01376297
3.5.2. Clinical Trial Detail – 2
188.8.131.52. Trials Id - NCT01339260
3.6. Unmet Needs in CINV Market
3.7. Factors influential to the sales of Netupitant - Palonosetron FDC
3.8. Sales Projection: Netupitant - Palonosetron FDC
3.8.1. Global Target Patient Pool
3.8.2. Global Forecasted Sales in $ in 000\'s
3.9. SWOT Analysis
3.10. Overall License Agreement for Netupitant - Palonosetron FDC
3.10.2. United States
3.10.5. UK & Ireland
3.10.6. South Korea
3.11. Company Profile – Helsinn Group